메뉴 건너뛰기




Volumn 22, Issue 6, 2016, Pages 1348-1355

A phase i first-in-human study of nesvacumab (REGN910), a fully human anti-angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; NESVACUMAB; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

EID: 84962232352     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1221     Document Type: Article
Times cited : (56)

References (37)
  • 1
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335-42.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 2
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6
  • 3
    • 84867047384 scopus 로고    scopus 로고
    • Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
    • Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506.
    • (2012) J Clin Oncol , vol.30 , pp. 3499-3506
    • Van Cutsem, E.1    Tabernero, J.2    Lakomy, R.3    Prenen, H.4    Prausova, J.5    Macarulla, T.6
  • 4
    • 84906903314 scopus 로고    scopus 로고
    • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial
    • Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384:665-73.
    • (2014) Lancet , vol.384 , pp. 665-673
    • Garon, E.B.1    Ciuleanu, T.E.2    Arrieta, O.3    Prabhash, K.4    Syrigos, K.N.5    Goksel, T.6
  • 5
    • 0030460424 scopus 로고    scopus 로고
    • Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
    • Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
    • (1996) Cell , vol.87 , pp. 1161-1169
    • Davis, S.1    Aldrich, T.H.2    Jones, P.F.3    Acheson, A.4    Compton, D.L.5    Jain, V.6
  • 7
    • 60749096085 scopus 로고    scopus 로고
    • Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
    • Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-77.
    • (2009) Nat Rev Mol Cell Biol , vol.10 , pp. 165-177
    • Augustin, H.G.1    Koh, G.Y.2    Thurston, G.3    Alitalo, K.4
  • 8
    • 84875807200 scopus 로고    scopus 로고
    • The complex role of angiopoietin-2 in the angiopoietin- tie signaling pathway
    • Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin- tie signaling pathway. Cold SpringHarb Perspect Med2012;2:a006550.
    • (2012) Cold SpringHarb Perspect Med , vol.2 , pp. a006550
    • Thurston, G.1    Daly, C.2
  • 9
    • 0030480322 scopus 로고    scopus 로고
    • Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
    • Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
    • (1996) Cell , vol.87 , pp. 1171-1180
    • Suri, C.1    Jones, P.F.2    Patan, S.3    Bartunkova, S.4    Maisonpierre, P.C.5    Davis, S.6
  • 10
    • 0034036689 scopus 로고    scopus 로고
    • Angiopoietin- 1 protects the adult vasculature against plasma leakage
    • Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin- 1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
    • (2000) Nat Med , vol.6 , pp. 460-463
    • Thurston, G.1    Rudge, J.S.2    Ioffe, E.3    Zhou, H.4    Ross, L.5    Croll, S.D.6
  • 11
    • 0033601357 scopus 로고    scopus 로고
    • Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
    • Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
    • (1999) Science , vol.286 , pp. 2511-2514
    • Thurston, G.1    Suri, C.2    Smith, K.3    McClain, J.4    Sato, T.N.5    Yancopoulos, G.D.6
  • 12
    • 73949105871 scopus 로고    scopus 로고
    • A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models
    • Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9:145-56.
    • (2010) Mol Cancer Ther , vol.9 , pp. 145-156
    • Brown, J.L.1    Cao, Z.A.2    Pinzon-Ortiz, M.3    Kendrew, J.4    Reimer, C.5    Wen, S.6
  • 13
    • 84871989305 scopus 로고    scopus 로고
    • Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition
    • Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73:108-18.
    • (2013) Cancer Res , vol.73 , pp. 108-118
    • Daly, C.1    Eichten, A.2    Castanaro, C.3    Pasnikowski, E.4    Adler, A.5    Lalani, A.S.6
  • 14
    • 73649112748 scopus 로고    scopus 로고
    • Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels
    • Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009;175:2159-70.
    • (2009) Am J Pathol , vol.175 , pp. 2159-2170
    • Falcon, B.L.1    Hashizume, H.2    Koumoutsakos, P.3    Chou, J.4    Bready, J.V.5    Coxon, A.6
  • 15
    • 60549103097 scopus 로고    scopus 로고
    • Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth
    • Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009;69:1324-33.
    • (2009) Cancer Res , vol.69 , pp. 1324-1333
    • Nasarre, P.1    Thomas, M.2    Kruse, K.3    Helfrich, I.4    Wolter, V.5    Deppermann, C.6
  • 16
    • 7944220649 scopus 로고    scopus 로고
    • Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin- 2
    • Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin- 2. Cancer Cell 2004;6:507-16.
    • (2004) Cancer Cell , vol.6 , pp. 507-516
    • Oliner, J.1    Min, H.2    Leal, J.3    Yu, D.4    Rao, S.5    You, E.6
  • 18
    • 63149188174 scopus 로고    scopus 로고
    • Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma
    • Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009;15: 1384-92.
    • (2009) Clin Cancer Res , vol.15 , pp. 1384-1392
    • Helfrich, I.1    Edler, L.2    Sucker, A.3    Thomas, M.4    Christian, S.5    Schadendorf, D.6
  • 20
    • 0031737425 scopus 로고    scopus 로고
    • Cell type-specific expression of angiopoietin- 1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis
    • Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin- 1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
    • (1998) Am J Pathol , vol.153 , pp. 1459-1466
    • Stratmann, A.1    Risau, W.2    Plate, K.H.3
  • 21
  • 22
    • 84859880607 scopus 로고    scopus 로고
    • Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma
    • Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
    • (2012) Clin Cancer Res , vol.18 , pp. 2290-2300
    • Llovet, J.M.1    Pena, C.E.2    Lathia, C.D.3    Shan, M.4    Meinhardt, G.5    Bruix, J.6
  • 23
    • 84907399835 scopus 로고    scopus 로고
    • Serum angiopoietin-2 and soluble VEGFR-2 levels predictmalignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer
    • Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predictmalignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer 2014;14:696.
    • (2014) BMC Cancer , vol.14 , pp. 696
    • Sallinen, H.1    Heikura, T.2    Koponen, J.3    Kosma, V.M.4    Heinonen, S.5    Yla-Herttuala, S.6
  • 25
    • 70249114453 scopus 로고    scopus 로고
    • Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
    • Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. JClin Oncol 2009;27:3557-65.
    • (2009) JClin Oncol , vol.27 , pp. 3557-3565
    • Herbst, R.S.1    Hong, D.2    Chap, L.3    Kurzrock, R.4    Jackson, E.5    Silverman, J.M.6
  • 26
    • 84956792410 scopus 로고    scopus 로고
    • A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors
    • Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, et al. A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2014;32:5s.
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Dowlati, A.1    Vlahovic, G.2    Natale, R.B.3    Rasmussen, E.4    Singh, I.5    Hwang, Y.C.6
  • 29
  • 30
    • 34547628176 scopus 로고    scopus 로고
    • Podocytespecific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia
    • Davis B, Dei Cas A, Long DA, White KE, Hayward A, Ku CH, et al. Podocytespecific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 2007;18:2320-9.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 2320-2329
    • Davis, B.1    Dei Cas, A.2    Long, D.A.3    White, K.E.4    Hayward, A.5    Ku, C.H.6
  • 31
    • 59949085812 scopus 로고    scopus 로고
    • Roles of angiopoietins in kidney development and disease
    • Woolf AS, Gnudi L, Long DA. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 2009;20:239-44.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 239-244
    • Woolf, A.S.1    Gnudi, L.2    Long, D.A.3
  • 34
    • 0035132684 scopus 로고    scopus 로고
    • Prevalence of cerebral white matter lesions in elderly people: A population based magnetic resonance imaging study. The Rotterdam Scan Study
    • de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The RotterdamScan Study. J Neurol Neurosurg Psychiatry 2001;70:9-14.
    • (2001) J Neurol Neurosurg Psychiatry , vol.70 , pp. 9-14
    • De Leeuw, F.E.1    De Groot, J.C.2    Achten, E.3    Oudkerk, M.4    Ramos, L.M.5    Heijboer, R.6
  • 35
    • 1942456802 scopus 로고    scopus 로고
    • The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals
    • Wen W, Sachdev P. The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals. Neuroimage 2004;22:144-54.
    • (2004) Neuroimage , vol.22 , pp. 144-154
    • Wen, W.1    Sachdev, P.2
  • 36
    • 84962300276 scopus 로고    scopus 로고
    • Clinical and biologic effects of the angiopoietin 1/2 neutralizing peptibody, trebananib (AMG 386), in acute myeloid leukemia patients
    • Orlando, FL (abstract 2701)
    • Wang ES, Fetterly G, Brady W, Tan W, Greene J, Gaudy A, et al. Clinical and biologic effects of the angiopoietin 1/2 neutralizing peptibody, trebananib (AMG 386), in acute myeloid leukemia patients. American Society of Hematology (ASH) 55th Annual Meeting, Orlando, FL (abstract 2701).
    • American Society of Hematology (ASH) 55th Annual Meeting
    • Wang, E.S.1    Fetterly, G.2    Brady, W.3    Tan, W.4    Greene, J.5    Gaudy, A.6
  • 37
    • 84902811306 scopus 로고    scopus 로고
    • A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin- 2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies
    • Papadopoulos KP, Graham DM, Tolcher AW, Razak ARA, Patnaik A, Bedard PL, et al. A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin- 2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies. J Clin Oncol 2014;32:5s.
    • (2014) J Clin Oncol , vol.32 , pp. 5s
    • Papadopoulos, K.P.1    Graham, D.M.2    Tolcher, A.W.3    Razak, A.R.A.4    Patnaik, A.5    Bedard, P.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.